Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Chen-Hao Kuo, Bo-Son Kou & Shau-Wei Tsai. (2020) CALB-catalyzed kinetic resolution of (RS)-3-benzoylthio-2-methylpropyl azolides: kinetic and thermodynamic analysis. Biocatalysis and Biotransformation 38:5, pages 376-384.
Read now
Read now
Stefano Omboni & Claudio Borghi. (2011) Zofenopril and incidence of cough: a review of published and unpublished data. Therapeutics and Clinical Risk Management 7, pages 459-471.
Read now
Read now
Peter Nilsson. (2007) Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Pressure 16:sup2, pages 25-30.
Read now
Read now
Krzysztof Narkiewicz. (2007) Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Pressure 16:sup2, pages 7-12.
Read now
Read now
Thomas Hedner, Krzysztof Narkiewicz & Sverre E. Kjeldsen. (2007) The evolution of ACE inhibition – A turning point in cardiovascular medicine. Blood Pressure 16:sup2, pages 5-6.
Read now
Read now
Articles from other publishers (10)
Benjamin Palić, Ivica Brizić, Emina Karahmet Sher, Ivona Cvetković, Amina Džidić-Krivić, Heba Taha Mohmmed Abdelghani & Farooq Sher. (2023) Effects of Zofenopril on Arterial Stiffness in Hypertension Patients. Molecular Biotechnology.
Crossref
Crossref
Elena Kutumova, Ilya Kiselev, Ruslan Sharipov, Galina Lifshits & Fedor Kolpakov. (2022) Mathematical modeling of antihypertensive therapy. Frontiers in Physiology 13.
Crossref
Crossref
Ebenezeri Erasto Ngowi, Muhammad Sarfraz, Attia Afzal, Nazeer Hussain Khan, Saadullah Khattak, Xin Zhang, Tao Li, Shao-Feng Duan, Xin-Ying Ji & Dong-Dong Wu. (2020) Roles of Hydrogen Sulfide Donors in Common Kidney Diseases. Frontiers in Pharmacology 11.
Crossref
Crossref
Ettore Malacco, Stefano Omboni & Gianfranco Parati. (2015) Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial. International Journal of Hypertension 2015, pages 1-12.
Crossref
Crossref
A A Kirichenko. (2014) Comparative evaluation of zofenopril. Are the characteristics of angiotensin I converting enzyme inhibitors important for the practice?. Systemic Hypertension 11:3, pages 39-43.
Crossref
Crossref
Enrico Agabiti-Rosei, Athanasios Manolis, Dario Zava & Stefano Omboni. (2014) Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients. Advances in Therapy 31:2, pages 217-233.
Crossref
Crossref
Thippani Ramesh, Pothuraju Nageswara Rao & Ramisetti Nageswara Rao. (2014) LC–MS/MS characterization of forced degradation products of zofenopril. Journal of Pharmaceutical and Biomedical Analysis 88, pages 609-616.
Crossref
Crossref
C. Napoli. (2011) Safety and efficacy of the sulfydryl ACE-inhibitor zofenopril in the management of cardiovascular disease. Cardiovascular Therapy and Prevention 10:6, pages 99-104.
Crossref
Crossref
Stefano Omboni, Ettore Malacco & Gianfranco Parati. (2009) Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions. Cardiovascular Therapeutics 27:4, pages 275-288.
Crossref
Crossref
Claudio Napoli. (2009) Safety and Efficacy of the bi-Sulfydryl ACE-Inhibitor Zofenopril in the Management of Cardiovascular Disease. Clinical Medicine. Therapeutics 1, pages CMT.S2796.
Crossref
Crossref